Alnylam vs. Ionis: Here's the Better Bad-News Buy
The sell-offs for both of these beaten-down biotech stocks appear to be overdone.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
More in Finance & Markets
Prediction: SpaceX Stock Won't Get Full Credit for Starship Until It Can Reuse the Whole Rocket
Key PointsStarship reached orbit for the first time on Sept. 28 and deployed 26 Starlink V3 satellites.
Investor doubts deepen as France’s debt pile nears 120pc of GDP ahead of presidential election
PARIS, Oct 10 — French government bonds have become the bane of investors on fears that officials are unwilling or...
Binance Launches $200K STABLE Trading Competition with New Multiplier Mechanics
Binance just kicked off a fresh trading competition, dangling a $200,000 prize pot for anyone engaging with the STABLE token.
- Binance launches $200K STABLE token trading competition
- New multiplier mechanics include Early Bird Boost and Rising Trader Boost
- Top 2,000 participants share 3,850,000 STABLE tokens
Berkshire Hathaway and Mastercard Don't Need AI to Keep Growing. Both Look Worth Owning Through 2030.
Neither company needs a data center boom to keep growing. Is that worth owning for the next four years?
The Stock Market Flashes a Warning as Investors Get Bad News About President Trump’s Economy. History Says This Will Happen Next.
Consumer sentiment continued to decline in October due to persistent inflationary pressure created by President Trump's policies.
